Intracerebral haemorrhage: mechanisms of injury and therapeutic targets

By R. Keep, Y. Hua, G. Xi. Lancet Neurology, 2012

1,158 citations recorded by the source corpus.

Intracerebral haemorrhage (ICH) accounts for about 10–15% of all strokes. ICH is associated with high mortality and morbidity and there has been no successful Phase III clinical trial for this condition. The last six years has seen a great increase in the number of pre-clinical and clinical studies focused on ICH. There have been significant advances in the animal models available to study ICH and in our understanding of the mechanisms underlying brain injury following haemorrhage. This has led to the identification of several therapeutic targets that are now being pursued into clinical trials. These advances are described in this review in addition to information on past and current clinical trials. Many of the former were based on very limited pre-clinical data and possible guidelines on the nature of pre-clinical results that justify proceeding to the clinic are discussed.

Subfields: Epidemiology, Molecular Biology, Neurology

View Paper: https://www.semanticscholar.org/paper/1f2bcc1106e7e2d57c7869a750cc2c8f8ad26397

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. J. An
2. B. Yoon
3. T. J. Kim

Citations in the corpus

• Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update (2017, background): “However, compared to ischemic stroke, ICH leads to higher mortality and more severe disability.(7) In this review, we will summarize the epidemiology, pathophysiology, risk factors, prognostic factors, and clinical manifestation of ICH.”
• Selenium Drives a Transcriptional Adaptive Program to Block Ferroptosis and Treat Stroke. (2019, neutral): “, 2010), there are no established treatments (Keep et al., 2012).”